SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SCYNEXIS reported Q3 2024 financial results, highlighting the receipt of a $10 million milestone payment from GSK following the delivery of clinical study reports for FURI, CARES, and NATURE trials. The company reported revenue of $0.7 million, R&D expenses of $8.1 million, and a net loss of $2.8 million. Cash position stands at $84.9 million, providing runway into Q3 2026. SCY-247, their second-generation antifungal, showed promising preclinical results, with Phase 1 trials expected to begin in Q4 2024. The Phase 3 MARIO trial in invasive candidiasis is anticipated to restart in Q1 2025.
SCYNEXIS ha riportato i risultati finanziari del terzo trimestre 2024, evidenziando il ricevimento di un pagamento di 10 milioni di dollari da GSK a seguito della consegna dei rapporti sugli studi clinici per i trial FURI, CARES e NATURE. L'azienda ha registrato un fatturato di 0,7 milioni di dollari, spese per R&D di 8,1 milioni di dollari e una perdita netta di 2,8 milioni di dollari. La posizione di cassa è di 84,9 milioni di dollari, garantendo liquidità fino al terzo trimestre del 2026. SCY-247, il loro antifungino di seconda generazione, ha mostrato risultati preclinici promettenti, con l'inizio dei trial di Fase 1 previsto per il quarto trimestre del 2024. Il trial di Fase 3 MARIO per la candidiasi invasiva è atteso per riprendere nel primo trimestre del 2025.
SCYNEXIS reportó los resultados financieros del tercer trimestre de 2024, destacando la recepción de un pago de 10 millones de dólares por parte de GSK tras la entrega de los informes de estudios clínicos para los ensayos FURI, CARES y NATURE. La compañía reportó ingresos de 0,7 millones de dólares, gastos de I+D de 8,1 millones de dólares y una pérdida neta de 2,8 millones de dólares. La posición de efectivo se sitúa en 84,9 millones de dólares, proporcionando recursos hasta el tercer trimestre de 2026. SCY-247, su antifúngico de segunda generación, mostró resultados preclínicos prometedores, con ensayos de Fase 1 previstos para comenzar en el cuarto trimestre de 2024. Se anticipa que el ensayo de Fase 3 MARIO en candidiasis invasiva se reinicie en el primer trimestre de 2025.
SCYNEXIS는 2024년 3분기 재무 결과를 보고하며, FURI, CARES 및 NATURE 시험의 임상 연구 보고서를 전달한 후 GSK로부터 1천만 달러의 이정표 지급을 받았음을 강조했습니다. 회사는 70만 달러의 수익, 810만 달러의 연구개발 비용, 그리고 280만 달러의 순손실을 보고했습니다. 현금 보유액은 8천490만 달러로, 2026년 3분기까지의 운영 자금을 제공합니다. 그들의 2세대 항진균제 SCY-247은 유망한 전임상 결과를 보였으며, 2024년 4분기에 1상 시험이 시작될 예정입니다. 침습성 칸디다증에 대한 3상 MARIO 시험은 2025년 1분기 중 재개될 것으로 예상됩니다.
SCYNEXIS a annoncé les résultats financiers du troisième trimestre 2024, mettant en évidence la réception d'un paiement de 10 millions de dollars de GSK après la livraison des rapports d'études cliniques pour les essais FURI, CARES et NATURE. La société a déclaré un revenu de 0,7 million de dollars, des dépenses en R&D de 8,1 millions de dollars et une perte nette de 2,8 millions de dollars. La position de trésorerie est de 84,9 millions de dollars, assurant une marge de manœuvre jusqu'au troisième trimestre 2026. SCY-247, leur antifongique de deuxième génération, a montré des résultats précliniques prometteurs, avec des essais de phase 1 prévus pour débuter au quatrième trimestre 2024. L'essai de phase 3 MARIO sur la candidose invasive devrait redémarrer au premier trimestre 2025.
SCYNEXIS hat die finanziellen Ergebnisse für das dritte Quartal 2024 veröffentlicht und dabei den Erhalt einer Zahlung von 10 Millionen Dollar von GSK hervorgehoben, die nach der Lieferung der klinischen Studienberichte für die FURI-, CARES- und NATURE-Studien erfolgte. Das Unternehmen berichtete von Einnahmen in Höhe von 0,7 Millionen Dollar, F&E-Ausgaben von 8,1 Millionen Dollar und einem Nettverlust von 2,8 Millionen Dollar. Die Liquiditätsposition liegt bei 84,9 Millionen Dollar, was finanzielle Mittel bis zum 3. Quartal 2026 sichert. SCY-247, ihr Zweigenerationen-Antimykotikum, zeigte vielversprechende präklinische Ergebnisse, wobei die Phase-1-Studien für das 4. Quartal 2024 erwartet werden. Die Phase-3-Studie MARIO zur invasiven Candidose wird voraussichtlich im 1. Quartal 2025 wieder aufgenommen.
- Received $10 million milestone payment from GSK partnership
- Strong cash position of $84.9 million providing runway into Q3 2026
- 42% decrease in SG&A expenses to $2.9 million
- Positive preclinical results for SCY-247 across multiple infection models
- Revenue decreased 71% to $0.7 million from $2.4 million YoY
- R&D expenses increased 25% to $8.1 million
- Net loss increased to $2.8 million from $1.8 million YoY
- Cash position decreased from $98.0 million to $84.9 million since December 2023
Insights
The Q3 2024 results reveal mixed financial performance. While SCYNEXIS received a significant
The company's cash position remains strong at
The advancement of SCY-247, SCYNEXIS's second-generation fungerp, shows promising preclinical results across multiple fungal infection models. Key findings include efficacy against Candida albicans and Candida glabrata, with significant reductions in organ fungal burden. The planned Phase 1 trial initiation in Q4 2024 represents a important development milestone.
The completion of FURI, CARES and NATURE trials for ibrexafungerp in refractory invasive fungal infections yielded positive results. The anticipated restart of the Phase 3 MARIO trial in invasive candidiasis in Q1 2025 indicates continued progress in clinical development, though manufacturing delays have impacted the timeline.
- Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a
$10 million development milestone payment to SCYNEXIS, received in Q3 2024.
- SCY-247 preclinical studies were presented at medical conferences and continue to show potent and broad antifungal activity. Phase 1 study initiation is anticipated in Q4 2024.
- SCYNEXIS ended Q3 2024 with cash, cash equivalents and investments of
$84.9 million , including the recently earned$10.0 million development milestone, and projects a cash runway into Q3 2026.
- SCYNEXIS will attend Guggenheim’s Inaugural Global Healthcare Conference in Boston on November 12thand hold one-on-one meetings with investors.
JERSEY CITY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended September 30, 2024.
“We see substantial value in our ibrexafungerp partnered programs and have been making significant progress advancing the manufacturing of clinical trial materials, which would enable the re-start of the Phase 3 MARIO trial in invasive candidiasis, anticipated in early 2025.” said David Angulo, M.D., President and Chief Executive Officer. “Additionally, SCY-247 has demonstrated highly encouraging preclinical results in a broad range of invasive fungal infections, underscoring its potential to be a new therapeutic to fight hard-to-treat fungal pathogens. We continue to share these promising results with the scientific community, most recently at IDWeek 2024. A planned Phase 1 trial of SCY-247 remains on track to initiate in the fourth quarter of 2024. We are also pleased to have completed the FURI, CARES and NATURE studies of ibrexafungerp in refractory invasive fungal infections, which showed positive results consistent with results reported from previous interim analyses. Delivery of final study reports to our partner triggered a
SCY-247 Preclinical Development Program
- Preclinical data from studies of SCY-247, the second generation fungerp from SCYNEXIS’ proprietary antifungal platform, were presented at multiple medical meetings, including the Mycoses Study Group Education & Research Consortium (MSGERC) Biennial Meeting in September 2024 and IDWeek in October 2024. These presentations highlighted encouraging preclinical efficacy and pharmacokinetic data on SCY-247 in multiple models of invasive fungal infections, including:
- Positive dose-dependent efficacy against Candida albicans mouse model following oral administration;
- Significant and dose-dependent reductions in kidney and lung fungal burden in Candida glabrata mouse model;
- Prolonged survival and reductions in lung and brain fungal burden in a pulmonary mucormycosis mouse model; and
- High tissue distribution into organs of concern for invasive fungal infections.
- Phase I initiation continues to be anticipated in Q4 2024.
Ibrexafungerp Clinical Updates
- Final study reports from the completed FURI, CARES and NATURE studies were delivered to partner, GSK in July 2024. Delivery of these reports triggered a
$10 million development milestone payment to SCYNEXIS which was received in the third quarter of 2024. Results from the FURI and CARES studies are planned to be presented by GSK at a future medical meeting. For more information on the trials, please visit ClinicalTrials.gov (CARES: NCT03363841; FURI: NCT03059992).
- Third-party manufacturing of new batches of ibrexafungerp for use in clinical trials is in progress, and SCYNEXIS anticipates restarting the Phase 3 MARIO study in invasive candidiasis in Q1 2025.
Guggenheim Conference Participation
Scynexis management will be participating in the Guggenheim Securities Healthcare Conference, taking place in Boston from November 11-13, 2024. Please contact your Guggenheim representative to schedule a meeting with the team.
Date: November 12, 2024
Format: 1x1 Meetings
Third Quarter 2024 Financial Results
For the three months ended September 30, 2024 and 2023, revenue primarily consists of
Research and development expense for the three months ended September 30, 2024 was
SG&A expense for the three months ended September 30, 2024 decreased to
Total other income was
Net loss for the three months ended September 30, 2024, was
Cash Balance
Cash, cash equivalents and investments totaled
About Triterpenoid Antifungals
Triterpenoid antifungals (also known as “fungerps”) are a novel class of structurally distinct glucan synthase inhibitors that combine the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. They have demonstrated broad-spectrum antifungal activity against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains. Ibrexafungerp is the first representative of this novel class of antifungal agents. Ibrexafungerp, formerly known as SCY-078, is currently approved in the U.S. for the treatment of vulvovaginal candidiasis and is in late-stage of development for invasive candidiasis and other indications. SCY-247 is a next generation fungerp in pre-clinical development for the treatment of life-threatening and often multi-drug-resistant fungal diseases including Candida auris infections.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. Additional antifungal assets from this novel class are currently in pre-clinical and discovery phase, including the compound SCY-247. For more information, visit www.scynexis.com.
Forward-Looking Statements
Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: SCYNEXIS’s expectation that it will have a cash runway into Q3 2026; anticipated initiation of Phase 1 clinical studies of SCY-247 in Q4 of 2024; and the anticipated resumption of the Phase 3 MARIO study. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 28, 2024, and form 10-Q for the quarter ending September 30, 2024, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com
SCYNEXIS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) | |||||||||
Three Months Ended September 30, | |||||||||
2024 | 2023 | ||||||||
Revenue: | |||||||||
Product (loss) revenue, net | $ | — | $ | (614 | ) | ||||
License agreement revenue | 660 | 2,375 | |||||||
Total revenue | 660 | 1,761 | |||||||
Operating expenses: | |||||||||
Cost of product revenue | — | 379 | |||||||
Research and development | 8,073 | 6,466 | |||||||
Selling, general and administrative | 2,907 | 5,014 | |||||||
Total operating expenses | 10,980 | 11,859 | |||||||
Loss from operations | (10,320 | ) | (10,098 | ) | |||||
Other (income) expense: | |||||||||
Amortization of debt issuance costs and discount | 441 | 360 | |||||||
Interest income | (1,020 | ) | (1,263 | ) | |||||
Interest expense | 213 | 212 | |||||||
Warrant liabilities fair value adjustment | (6,751 | ) | (7,468 | ) | |||||
Derivative liabilities fair value adjustment | — | (182 | ) | ||||||
Total other income | (7,117 | ) | (8,341 | ) | |||||
Loss before taxes | (3,203 | ) | (1,757 | ) | |||||
Income tax benefit | (395 | ) | — | ||||||
Net loss | $ | (2,808 | ) | $ | (1,757 | ) | |||
Net loss per share attributable to common stockholders – basic | |||||||||
Net loss per share – basic | $ | (0.06 | ) | $ | (0.04 | ) | |||
Net loss per share attributable to common stockholders – diluted | |||||||||
Net loss per share – diluted | $ | (0.06 | ) | $ | (0.04 | ) | |||
Weighted average common shares outstanding – basic and diluted | |||||||||
Basic | 48,618,693 | 47,891,996 | |||||||
Diluted | 48,618,693 | 47,891,996 | |||||||
SCYNEXIS, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) | |||||||||
September 30, 2024 | December 31, 2023 | ||||||||
Assets | |||||||||
Current assets: | |||||||||
Cash and cash equivalents | $ | 28,730 | $ | 34,050 | |||||
Short-term investments | 40,098 | 40,312 | |||||||
Prepaid expenses and other current assets | 1,538 | 5,548 | |||||||
License agreement receivable | 153 | 2,463 | |||||||
License agreement contract asset | 9,509 | 19,363 | |||||||
Restricted cash | 435 | 380 | |||||||
Total current assets | 80,463 | 102,116 | |||||||
Investments | 16,116 | 23,594 | |||||||
Deferred offering costs | 187 | 175 | |||||||
Restricted cash | 109 | 163 | |||||||
Operating lease right-of-use asset | 2,163 | 2,364 | |||||||
Total assets | $ | 99,038 | $ | 128,412 | |||||
Liabilities and stockholders’ equity | |||||||||
Current liabilities: | |||||||||
Accounts payable | $ | 4,955 | $ | 7,149 | |||||
Accrued expenses | 5,508 | 7,495 | |||||||
Deferred revenue, current portion | 1,642 | 1,189 | |||||||
Operating lease liability, current portion | 389 | 340 | |||||||
Warrant liabilities | — | 130 | |||||||
Convertible debt and derivative liability | 13,225 | — | |||||||
Total current liabilities | 25,719 | 16,303 | |||||||
Deferred revenue | 1,294 | 2,727 | |||||||
Warrant liabilities | 11,212 | 21,680 | |||||||
Convertible debt and derivative liability | — | 12,159 | |||||||
Operating lease liability | 2,284 | 2,581 | |||||||
Total liabilities | 40,509 | 55,450 | |||||||
Commitments and contingencies | |||||||||
Stockholders’ equity: | |||||||||
Preferred stock, | — | — | |||||||
Common stock, | 41 | 40 | |||||||
Additional paid-in capital | 430,590 | 428,169 | |||||||
Accumulated deficit | (372,102 | ) | (355,247 | ) | |||||
Total stockholders’ equity | 58,529 | 72,962 | |||||||
Total liabilities and stockholders’ equity | $ | 99,038 | $ | 128,412 | |||||
FAQ
What was SCYNEXIS (SCYX) revenue in Q3 2024?
When will SCYNEXIS (SCYX) begin Phase 1 trials for SCY-247?
What milestone payment did SCYNEXIS (SCYX) receive from GSK in Q3 2024?